Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson's disease

J. L. Roybal, M. Endo, A. Radu, L. Gray, C. A. Todorow, P. W. Zoltick, Svetlana Lutsenko, A. W. Flake

Research output: Contribution to journalArticle

Abstract

The ideal gene therapy for metabolical liver disorders would target hepatocytes before the onset of disease and be durable, non-toxic and non-immunogenic. Early gestational gene transfer can achieve such goals. Here, we demonstrate that prenatal gene transfer of human Atp7b reduces liver pathology and improves biochemical markers in Atp7b / mice, a murine model of Wilson's disease (WD). Following prenatal injection of lentivirus vector containing the human Atp7b gene under the transcriptional control of a liver-specific promoter, the full-length ATP7B was detectable in mouse livers for the entire duration of experiments (20 weeks after birth). In contrast to a marked pathology in non-injected animals, livers from age-matched treated mice consistently demonstrated normal gross and histological morphology. Hepatic copper content was decreased in the majority of treated mice, although remaining copper levels varied. Improvement of hepatic copper metabolism was further apparent from the presence of copper-bound ceruloplasmin in the sera and normalization of the mRNA levels for HMG CoA-reductase. With this approach, the complete loss of copper transport function can be ameliorated, as evident from phenotypical improvement in treated Atp7b / mice. This study provides proof of principle for in utero gene therapy in WD and other liver-based enzyme deficiencies.

Original languageEnglish (US)
Pages (from-to)1085-1094
Number of pages10
JournalGene Therapy
Volume19
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Hepatolenticular Degeneration
Phenotype
Liver
Copper
Genes
Genetic Therapy
Pathology
Hydroxymethylglutaryl CoA Reductases
Lentivirus
Ceruloplasmin
Hepatocytes
Biomarkers
Parturition
Messenger RNA
Injections
Enzymes
Serum

Keywords

  • ATP7B
  • Copper storage disease
  • Lentivirus
  • Prenatal

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Roybal, J. L., Endo, M., Radu, A., Gray, L., Todorow, C. A., Zoltick, P. W., ... Flake, A. W. (2012). Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson's disease. Gene Therapy, 19(11), 1085-1094. https://doi.org/10.1038/gt.2011.186

Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson's disease. / Roybal, J. L.; Endo, M.; Radu, A.; Gray, L.; Todorow, C. A.; Zoltick, P. W.; Lutsenko, Svetlana; Flake, A. W.

In: Gene Therapy, Vol. 19, No. 11, 11.2012, p. 1085-1094.

Research output: Contribution to journalArticle

Roybal, J. L. ; Endo, M. ; Radu, A. ; Gray, L. ; Todorow, C. A. ; Zoltick, P. W. ; Lutsenko, Svetlana ; Flake, A. W. / Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson's disease. In: Gene Therapy. 2012 ; Vol. 19, No. 11. pp. 1085-1094.
@article{74656b0087134c62a38b1d4543929d8f,
title = "Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson's disease",
abstract = "The ideal gene therapy for metabolical liver disorders would target hepatocytes before the onset of disease and be durable, non-toxic and non-immunogenic. Early gestational gene transfer can achieve such goals. Here, we demonstrate that prenatal gene transfer of human Atp7b reduces liver pathology and improves biochemical markers in Atp7b / mice, a murine model of Wilson's disease (WD). Following prenatal injection of lentivirus vector containing the human Atp7b gene under the transcriptional control of a liver-specific promoter, the full-length ATP7B was detectable in mouse livers for the entire duration of experiments (20 weeks after birth). In contrast to a marked pathology in non-injected animals, livers from age-matched treated mice consistently demonstrated normal gross and histological morphology. Hepatic copper content was decreased in the majority of treated mice, although remaining copper levels varied. Improvement of hepatic copper metabolism was further apparent from the presence of copper-bound ceruloplasmin in the sera and normalization of the mRNA levels for HMG CoA-reductase. With this approach, the complete loss of copper transport function can be ameliorated, as evident from phenotypical improvement in treated Atp7b / mice. This study provides proof of principle for in utero gene therapy in WD and other liver-based enzyme deficiencies.",
keywords = "ATP7B, Copper storage disease, Lentivirus, Prenatal",
author = "Roybal, {J. L.} and M. Endo and A. Radu and L. Gray and Todorow, {C. A.} and Zoltick, {P. W.} and Svetlana Lutsenko and Flake, {A. W.}",
year = "2012",
month = "11",
doi = "10.1038/gt.2011.186",
language = "English (US)",
volume = "19",
pages = "1085--1094",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson's disease

AU - Roybal, J. L.

AU - Endo, M.

AU - Radu, A.

AU - Gray, L.

AU - Todorow, C. A.

AU - Zoltick, P. W.

AU - Lutsenko, Svetlana

AU - Flake, A. W.

PY - 2012/11

Y1 - 2012/11

N2 - The ideal gene therapy for metabolical liver disorders would target hepatocytes before the onset of disease and be durable, non-toxic and non-immunogenic. Early gestational gene transfer can achieve such goals. Here, we demonstrate that prenatal gene transfer of human Atp7b reduces liver pathology and improves biochemical markers in Atp7b / mice, a murine model of Wilson's disease (WD). Following prenatal injection of lentivirus vector containing the human Atp7b gene under the transcriptional control of a liver-specific promoter, the full-length ATP7B was detectable in mouse livers for the entire duration of experiments (20 weeks after birth). In contrast to a marked pathology in non-injected animals, livers from age-matched treated mice consistently demonstrated normal gross and histological morphology. Hepatic copper content was decreased in the majority of treated mice, although remaining copper levels varied. Improvement of hepatic copper metabolism was further apparent from the presence of copper-bound ceruloplasmin in the sera and normalization of the mRNA levels for HMG CoA-reductase. With this approach, the complete loss of copper transport function can be ameliorated, as evident from phenotypical improvement in treated Atp7b / mice. This study provides proof of principle for in utero gene therapy in WD and other liver-based enzyme deficiencies.

AB - The ideal gene therapy for metabolical liver disorders would target hepatocytes before the onset of disease and be durable, non-toxic and non-immunogenic. Early gestational gene transfer can achieve such goals. Here, we demonstrate that prenatal gene transfer of human Atp7b reduces liver pathology and improves biochemical markers in Atp7b / mice, a murine model of Wilson's disease (WD). Following prenatal injection of lentivirus vector containing the human Atp7b gene under the transcriptional control of a liver-specific promoter, the full-length ATP7B was detectable in mouse livers for the entire duration of experiments (20 weeks after birth). In contrast to a marked pathology in non-injected animals, livers from age-matched treated mice consistently demonstrated normal gross and histological morphology. Hepatic copper content was decreased in the majority of treated mice, although remaining copper levels varied. Improvement of hepatic copper metabolism was further apparent from the presence of copper-bound ceruloplasmin in the sera and normalization of the mRNA levels for HMG CoA-reductase. With this approach, the complete loss of copper transport function can be ameliorated, as evident from phenotypical improvement in treated Atp7b / mice. This study provides proof of principle for in utero gene therapy in WD and other liver-based enzyme deficiencies.

KW - ATP7B

KW - Copper storage disease

KW - Lentivirus

KW - Prenatal

UR - http://www.scopus.com/inward/record.url?scp=84869082162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869082162&partnerID=8YFLogxK

U2 - 10.1038/gt.2011.186

DO - 10.1038/gt.2011.186

M3 - Article

C2 - 22158007

AN - SCOPUS:84869082162

VL - 19

SP - 1085

EP - 1094

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 11

ER -